A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: BIOLOGICAL: PF-05280014|DRUG: Paclitaxel|BIOLOGICAL: Herceptin®|DRUG: Paclitaxel
Sponsor: Pfizer